NTLA — Intellia Therapeutics Share Price
0.000.00%
Last trade - 00:00- $2.16bn
- $1.37bn
- $36.28m
- 55
- 12
- 26
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.26 | ||
| Price to Tang. Book | 2.26 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 43.91 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -42.89% | ||
| Return on Equity | -41.89% | ||
| Operating Margin | -936.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 43.1 | 57.99 | 33.05 | 52.12 | 36.27 | 70.78 | 67.89 | 3.57% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.
Directors
- Frank Verwiel NEC (59)
- John Leonard PRE (63)
- Glenn Goddard CFO (50)
- Laura Sepp-Lorenzino EVP (60)
- James Basta EVP (55)
- David Lebwohl EVP (66)
- Frederick Cohen IND (64)
- John Crowley IND (54)
- Caroline Dorsa IND (62)
- Jean-Francois Formela IND (64)
- Jesse Goodman IND (69)
- Georgia Keresty IND (60)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- May 7th, 2014
- Public Since
- May 6th, 2016
- No. of Shareholders
- 14
- No. of Employees
- 526
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 96,475,421
- Address
- 40 Erie St Ste 130, CAMBRIDGE, 02139-4254
- Web
- https://www.intelliatx.com/
- Phone
- +1 8572856200
- Contact
- Lina Li
- Auditors
- Deloitte & Touche LLP
Upcoming Events for NTLA
Q3 2024 Intellia Therapeutics Inc Earnings Release
Similar to NTLA
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Intellia Therapeutics share price?
As of Today at 21:22 UTC, shares in Intellia Therapeutics are trading at $24.22. This share price information is delayed by 15 minutes.
How has the Intellia Therapeutics share price performed this year?
Shares in Intellia Therapeutics last closed at $24.22 and the price had moved by -42.31% over the past 365 days. In terms of relative price strength the Intellia Therapeutics share price has underperformed the S&P500 Index by -54.09% over the past year.
What are the analyst and broker recommendations for Intellia Therapeutics?
The overall consensus recommendation for Intellia Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Intellia Therapeutics dividend yield?
Intellia Therapeutics does not currently pay a dividend.
Does Intellia Therapeutics pay a dividend?
Intellia Therapeutics does not currently pay a dividend.
When does Intellia Therapeutics next pay dividends?
Intellia Therapeutics does not currently pay a dividend.
How do I buy Intellia Therapeutics shares?
To buy shares in Intellia Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Intellia Therapeutics?
As of the previous close price of $24.22, shares in Intellia Therapeutics had a market capitalisation of $2.34bn.
Where are Intellia Therapeutics shares listed?
Here are the trading details for Intellia Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: NTLA
What kind of share is Intellia Therapeutics?
Based on an overall assessment of its quality, value and momentum Intellia Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Intellia Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Intellia Therapeutics is $69.61. That is 187.41% above the last closing price of $24.22.
Analysts covering Intellia Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$5.15 for the next financial year.
What is the trend in the Intellia Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Intellia Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -32.52%.
As of the last closing price of $24.22, shares in Intellia Therapeutics were trading -12.14% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Intellia Therapeutics PE Ratio?
The Intellia Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $24.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Intellia Therapeutics?
Intellia Therapeutics' management team is headed by:
- Frank Verwiel - NEC
- John Leonard - PRE
- Glenn Goddard - CFO
- Laura Sepp-Lorenzino - EVP
- James Basta - EVP
- David Lebwohl - EVP
- Frederick Cohen - IND
- John Crowley - IND
- Caroline Dorsa - IND
- Jean-Francois Formela - IND
- Jesse Goodman - IND
- Georgia Keresty - IND